88 related articles for article (PubMed ID: 2766272)
1. Metabolism and murine pharmacokinetics of the 8-(N,N-dimethylcarboxamide) analogue of the experimental antitumor drug mitozolomide (NSC353451).
Horspool KR; Quarterman CP; Slack JA; Gescher A; Stevens MF; Lunt E
Cancer Res; 1989 Sep; 49(18):5023-6. PubMed ID: 2766272
[TBL] [Abstract][Full Text] [Related]
2. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
[TBL] [Abstract][Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
6. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and mechanism of the antileukemic action of isomeric aryldimethyltriazenes.
Sava G; Giraldi T; Lassiani L; Nisi C
Cancer Treat Rep; 1982 Sep; 66(9):1751-5. PubMed ID: 7116350
[TBL] [Abstract][Full Text] [Related]
9. In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans.
Calabrese CR; Loadman PM; Lim LS; Bibby MC; Double JA; Brown JE; Lamb JH
Drug Metab Dispos; 1999 Feb; 27(2):240-5. PubMed ID: 9929509
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and metabolism of orally administered mitozolomide in mice.
Gachon F; Labarre P; Godeneche D; Moreau MF; Papon J; Madelmont JC; Veyre A; Gaillard G
Drug Metab Dispos; 1993; 21(4):560-6. PubMed ID: 8104113
[TBL] [Abstract][Full Text] [Related]
12. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
14. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
16. Plasma and tissue disposition of mitozolomide in mice.
Brindley CJ; Antoniw P; Newlands ES
Br J Cancer; 1986 Jan; 53(1):91-7. PubMed ID: 3456242
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans.
Ames MM; Kovach JS; Rubin J
Cancer Res; 1984 Sep; 44(9):4151-6. PubMed ID: 6744326
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
[TBL] [Abstract][Full Text] [Related]
19. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
